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Abstract
Background: The infants born to women who are overweight or obese in pregnancy are at an increased risk of
being born macrosomic or large for gestational age. Antenatal dietary and lifestyle interventions have been shown
to be ineffective at reducing this risk. Our aim was to examine the effects of metformin in addition to a diet and
lifestyle intervention on fetal growth and adiposity among women with a BMI above the healthy range.
Methods: Women who had a body mass index ≥25 kg/m2 in early pregnancy, and a singleton gestation, were
enrolled in the GRoW trial from three public maternity hospitals in metropolitan Adelaide. Women were invited to
have a research ultrasounds at 28 and 36 weeks’ gestation at which ultrasound measures of fetal biometry and
adiposity were obtained. Fetal biometry z-scores and trajectories were calculated. Measurements and calculations
were compared between treatment groups. This secondary analysis was pre-specified.
Results: Ultrasound data from 511 women were included in this analysis. The difference in femur length at 36
weeks’ gestation was (0.07 cm, 95% CI 0.01–0.14 cm, p = 0.019) and this was was statistically significant, however the
magnitude of effect was small. Differences between treatment groups for all other fetal biometry measures, z-
scores, estimated fetal weight, and adiposity measures at 28 and 36 weeks’ gestation were similar.
Conclusions: The addition of metformin to dietary and lifestyle advice in pregnancy for overweight and obese
women has no clinically relevant effect on ultrasound measures of fetal biometry or adiposity.
Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN12612001277831).
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Background
Women commencing pregnancy overweight or obese,
defined as a body mass index (BMI) of ≥ 25 kg/m2 and ≥
30 kg/m2, respectively,have an increased risk of adverse
pregnancy and birth outcomes. These adverse outcomes
include gestational diabetes (GDM) [1, 2] and hyperten-
sive disorders, including pre-eclampsia [1, 2], during
pregnancy and an increased risk of both induction of
labour [1, 3] and birth by caesarean section [1, 4]. In de-
veloped countries, overweight and obesity effects ap-
proximately 50% of women of reproductive age [5–7].
Infants born to women who are overweight or obese
are at increased risk of being born macrosomic or large
for gestational age (LGA) [1, 8–10], of birth trauma in-
cluding shoulder dystocia [10, 11], low Apgar scores, re-
quiring resuscitation at birth [1, 8, 10], hypoglycaemia
[12, 13] and requiring neonatal intensive care admission
[1, 8, 12]. Longer term, maternal overweight and obesity
are independent risk factors for childhood obesity [14–
16], which may be partially mediated through an in-
creased risk of infant macrosomia [17].
Antenatal dietary and lifestyle interventions have not
been effective in reducing the risk of adverse clinical
pregnancy and birth outcomes [18–20]. In particular,
such interventions have not reduced infant birthweight
or risk of an infant born LGA [18].
Oral metformin, a commonly used insulin sensitising
agent, has been evaluated as a strategy to improve preg-
nancy outcomes for overweight and obese women, given
similarities in the metabolic environment between both
obesity and GDM. However, studies investigating the ef-
fects of antenatal metformin have either not reported
growth and development in utero [21], or been limited
in their analyses [22], resulting in a dearth of informa-
tion about the fetal effects of antenatal metformin use.
Our group performed a randomised controlled trial in-
vestigating the effects of antenatal metformin therapy as
an adjuvant to diet and lifestyle advice for women who
were overweight or obese in early pregnancy [23]. We
have previously reported that adjuvant antenatal metfor-
min therapy is not associated with any differences in
birth weight or risk of infants being born large for gesta-
tional age [23]. However, whether adjuvant antenatal
metformin therapy has an effect on fetal growth, adipos-
ity, and growth velocity, is not known. The aim of this
pre-specified analysis of secondary outcomes was to in-
vestigate the effect of this combined antenatal interven-
tion on fetal growth and adiposity.
Methods
Participants
The primary findings of the GRoW randomised trial [23]
have been published. Women with a singleton, live gesta-
tion who were overweight or obese (BMI ≥25.0 kg/m2)
and between 10 and 20 weeks’ gestation, were eligible to
participate. Women with a multiple pregnancy, pre-
existing type 1 or type 2 diabetes mellitus, or a contraindi-
cation to taking metformin were excluded from the study.
Randomisation
Potentially eligible women were identified and recruited
from three major public maternity hospitals in metro-
politan Adelaide – the Women’s and Children’s Hos-
pital, the Lyell McEwin Hospital, and Flinders Medical
Centre. Informed consent was obtained. Randomisation
used a central computer-based randomisation service,
with variable blocks of four. Women were stratified ac-
cording to parity (0 vs ≥1), BMI at booking visit (25–
29.9 kg/m2 vs ≥30 kg/m2), and collaborating centre.
Women, their caregivers, and research staff were blinded
to treatment allocation.
Intervention
Participating women were randomised to either the met-
formin group or placebo group. Women recruited to the
metformin group received a supply of oral metformin
tablets (500 mg) and women allocated to the placebo
group received a supply of placebo tablets identical in
taste and appearance to the metformin tablets. All
women were instructed to start taking one tablet per day
increasing to a maximum of two tablets twice daily over
four weeks as tolerated, and to continue over the course
of the pregnancy [23].
All women received a dietary and lifestyle intervention
over the course of the study, which we have described in
detail previously [23]. This was an individually tailored
intervention, and involved three face-to-face sessions
over the course of pregnancy (the initial two with a
dietitian, and one with a research assistant at 36 weeks’
gestation) and phone calls. Dietary advice was provided,
in keeping with Australian dietary standards. This in-
cluded maintaining a balance of carbohydrates, fat and
protein, and reducing energy dense foods high in refined
carbohydrates and saturated fats. Women were recom-
mended to consume two servings of fruit, five servings
of vegetables, and three servings of dairy each day.
Women were encouraged to set and review achievable
diet and lifestyle goals and self monitor their progress.
Ultrasound assessment
An accurate gestational age and estimated date of con-
finement was calculated for each woman based on early
pregnancy ultrasound or last menstrual period. Women
underwent a routine fetal anomaly scan at 18–20 weeks’
gestation, in keeping with South Australian Perinatal
Practice Guidelines [24]. Participating women gave per-
mission for fetal biometry results from this scan to be
made available to the researchers. All women were
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invited to attend for a research ultrasound at 28 (range
26+ 0 to 29+ 6) and 36 (range 34+ 0 to 37+ 6) weeks’ gesta-
tion. A medical practitioner with specialist or subspecial-
ist training in obstetric ultrasound performed all
research ultrasounds, and was blinded to the woman’s
allocated treatment group.
Fetal biometry measures
Fetal biometry measures collected from the routine fetal
anomaly scan at 18–20 weeks’ gestation included stand-
ard measurements of head circumference (HC), biparie-
tal diameter (BPD), abdominal circumference (AC) and
femur length (FL). At the research ultrasounds, measure-
ments of standard fetal biometry (HC, BPD, AC, and FL)
were obtained in accordance with national and inter-
national standards of practice [25]. Biometry measures
obtained from the research ultrasounds were converted
into z scores to allow for variation in gestational age and
fetal sex, using recognised Australian population stan-
dards [25, 26]. Estimated fetal weight (EFW) was calcu-
lated using the Hadlock C formula [27].
Fetal growth velocities
Fetal growth velocities are presented as the difference
between 28 week measures and 36 week measures, calcu-
lated as total change / actual number of days between
measurements. Velocity z-scores were likewise calcu-
lated using recognised Australian population standards
where available [28].
Fetal adiposity measures
Fetal subcutaneous tissue fat thickness measurements
were obtained at both research ultrasounds. These mea-
surements included mid thigh lean mass (MTLM), mid
thigh fat mass (MTFM), abdominal fat mass (AFM), and
subscapular fat mass (SSFM), and were obtained by
methods described previously [29–34]. Mid thigh total,
lean and fat mass were obtained by taking a longitudinal
view of the femur, then rotating the transducer through
90 degrees to obtain a cross-sectional view of the mid-
thigh [30, 31]. MTFM was measured by taking the total
cross-sectional limb area (MTTM) and subtracting
MTLM (consisting of the central lean area comprising
muscle and bone). Fetal AFM was measured at the level
of the abdominal circumference, between fetal mid-
axillary lines and anterior to the margins of the ribs [29,
30]. This was measured in millimetres and using magni-
fication. The SSFM was obtained by a sagittal view of
the fetal trunk, to view the entire longitudinal section of
the scapula. The subcutaneous fat tissue measurement
was taken at the level of the end of the scapula [30]. We
have previously shown good inter-observer variability for
these measurements in a similar cohort of women who
were overweight or obese in early pregnancy [33].
Statistical analysis
Baseline characteristics of women included in the ana-
lysis were compared descriptively between treatment
groups. Continuous variables were reported as means
and standard deviations, or as medians and interquartile
ranges if not normally distributed. Categorical variables
were reported as frequencies and percentages. Analyses
were performed on available data on an intention-to-
treat basis, with women analysed according to the treat-
ment group into which they were randomised.
Outcomes measured at multiple time points were ana-
lysed using linear regression models, with Generalised
Estimating Equations to account for correlation due to
repeated measures, and a time-by-treatment interaction
term to test for differences in treatment effect between
time points. Estimates are reported as differences in
means (metformin group – placebo group) and 95%
confidence intervals for each time point separately, re-
gardless of the significance of the interaction term.
Growth velocity outcomes were analysed using linear re-
gression models, with estimates again reported as differ-
ences in means (metformin group – placebo group) and
95% confidence intervals. Both unadjusted and adjusted
analyses were performed, with adjusted analyses includ-
ing stratification variables (study centre, BMI category
and parity), maternal age at trial entry, smoking status,
and Socio-Economic Indexes for Areas Index of Relative
Socio-Economic Disadvantage (SEIFA IRSD) quintile as
covariates. All analyses were performed using SAS v9.4
(SAS Institute, Cary, NC).
Results
Participant characteristics
A total of 524 women were recruited and randomised in
the GRoW randomised trial, with 261 (49.8%) women
randomised to the metformin group, and 263 (50.2%)
women randomised to the placebo group. Overall, 10
women withdrew, underwent a termination of preg-
nancy, or suffered a miscarriage before 20 weeks’ gesta-
tion, resulting in a total of 256 women and their infants
in the metformin group and 258 women and their in-
fants in the placebo group who were included in primary
analyses (Fig. 1). The present study includes a total of
511 women who attended for one or more research ul-
trasounds, 255 women from the metformin group and
256 women from the placebo group (Fig. 1).
Baseline demographic characteristics of participating
women are shown in Table 1, and were comparable be-
tween treatment groups. The median gestational age at
trial entry was 16.29 weeks (Interquartile Range (IQR)
14.43–18.00 weeks). The median BMI of the cohort was
32.30 kg/m2 (IQR 28.90–37.20 kg/m2), with most women
in their second or subsequent pregnancy, non-smokers,
and 62.63% from the highest two quintiles of social
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disadvantage [35]. These characteristics are similar to
the full randomised cohort [23].
Fetal biometry measures
There were no statistically significant differences in
fetal biometry measures of BPD, HC or AC at any of
the time points assessed (20 weeks’, 28 weeks’, and
36 weeks’ gestation; Table 2). Measurements of FL
were not statistically significantly different at 20 or
28 weeks’ gestation (Table 2). Average femur length
was statistically significantly greater in the metfor-
min group at 36 weeks’ gestation, however the mag-
nitude of the difference was small – only 0.07 (95%
CI: 0.01, 0.14) cm. There were no statistically signifi-
cant differences seen in calculated EFW at 28 or 36
weeks’ gestation, by treatment group (Table 2). The
estimates of effect size for fetal biometry measures
were all less than 0.50 cm and crossed zero (Table
2), suggesting that there were little to no absolute
differences in average fetal biometry measures be-
tween the metformin and placebo groups, and that
the true effect of treatment is not clinically relevant.
Similarly, the estimated effect size on estimated fetal
weight was only 17.61 (95% CI -57.67, 92.88) gm
(Table 2), again suggesting a clinically relevant effect
is unlikely.
In keeping with the above findings, there were no
statistically significant differences in the fetal biometry
z-scores of BPD, HC, FL or AC between the treat-
ment groups, at any of the time points assessed (sup-
plementary Table 1). There were no statistically
significant differences in calculated estimated fetal
weight z-score at 28 or 36 weeks’ gestation, by treat-
ment group (supplementary Table 1). There was no
evidence that the treatment effect differed between
time points. All fetal biometry measure z-scores were
positive in both groups, at all time points, suggesting
the fetuses of women in our study were larger on
average than the reference population used [26]. With
regards to fetal biometry velocities and estimated fetal
weight velocity, there were no statistically significant
differences by treatment group, either in the raw vel-
ocity measurements or velocity for z-score (supple-
mentary Table 2).
Fig. 1 Flow of women eligible for inclusion in the analysis of ultrasound measurements of fetal growth and adiposity in the GRoW
randomised trial
Poprzeczny et al. BMC Endocrine Disorders          (2020) 20:139 Page 4 of 9
Fetal adiposity measures
There was no statistically significant treatment effect on
any of the measures of fetal adiposity, at either 28 or 36
weeks’ gestation (Table 3). Estimates of effect size for all
adiposity measures were close to zero, and the range of
the 95% confidence intervals were small, suggesting a
clinically meaningful effect is unlikely.
Discussion
Main findings
Our findings demonstrate that, among pregnant women
who are overweight or obese, antenatal treatment with
oral metformin as an adjunct to dietary and lifestyle ad-
vice did not appreciably impact measures of fetal biom-
etry or adiposity, or fetal biometry growth velocities over
the third trimester of pregnancy.
Interpretation
Metformin has been used increasingly in the treatment
of GDM. The Metformin in Gestational Diabetes (MiG)
Trial confirmed the safety and efficacy of metformin use
in women with GDM [21]. Oral metformin was not as-
sociated with an increased rate of a composite neonatal
adverse outcome (made up of neonatal hypoglycaemia,
respiratory distress, need for phototherapy, birth trauma,
5-min Apgar < 7, or preterm birth) [21], confirming its
safety in pregnancy. Rowan et al also found no signifi-
cant differences between metformin and insulin with
regards to neonatal biometry, circumferences, or skin-
fold thickness measurements [21].
Subsequent childhood follow up at two years of age,
however, revealed selected differences with children ex-
posed to metformin in pregnancy having statistically sig-
nificantly greater upper arm circumference and
subscapular and biceps skinfold thicknesses, and greater
fat free mass measurements, in comparison with chil-
dren exposed to insulin antenatally [36]. It was hypothe-
sised that antenatal metformin caused fat to be stored in
subcutaneous sites, resulting in less ectopic or visceral
fat [36]. The MiG trial did not report fetal measures of








Maternal age (years; mean (SD)) 29.88 (5.55) 30.15 (5.38) 30.02 (5.46)
Gestational age at trial entry (weeks) Median (IQR) 16.29 (14.43, 18.00) 16.21 (14.57, 18.07) 16.29 (14.43, 18.00)
BMI (kg/m2) Median (IQR) 32.40 (28.70, 37.57) 32.05 (29.10, 36.80) 32.30 (28.90, 37.20)
BMI category (kg/m2) N (%):
BMI 25.0–29.9 83 (32.55) 83 (32.42) 166 (32.49)
BMI 30.0–34.9 74 (29.02) 83 (32.42) 157 (30.72)
BMI 35.0–39.9 58 (22.75) 48 (18.75) 106 (20.74)
BMI ≥ 40.0 40 (15.69) 42 (16.41) 82 (16.05)
Nulliparity N (%) 88 (34.51) 91 (35.55) 179 (35.03)
Smoker N (%) 24 (9.41) 43 (16.80) 67 (13.11)
Height at trial entry (cm)
Mean (SD)
165.24 (6.76) 164.89 (6.78) 165.07 (6.76)
Weight at trial entry (kg) Mean (SD) 92.86 (19.79) 91.87 (19.76) 92.36 (19.76)
Ethnicity N(%)
Caucasian 209 (81.96) 219 (85.55) 428 (83.76)
Asian 5 (1.96) 7 (2.73) 12 (2.35)
Aboriginal/Torres Strait Islander 6 (2.35) 7 (2.73) 13 (2.54)
African 6 (2.35) 0 (0.00) 6 (1.17)
Other/unknown 29 (11.38) 23 (8.98) 52 (10.18)
SEIFA IRSD Quintile N(%)
Quintile 1 75 (29.41) 93 (36.33) 168 (32.88)
Quintile 2 78 (30.59) 74 (28.91) 152 (29.75)
Quintile 3 31 (12.16) 30 (11.72) 61 (11.94)
Quintile 4 52 (20.39) 43 (16.80) 95 (18.59)
Quintile 5 19 (7.45) 16 (6.25) 35 (6.85)
Poprzeczny et al. BMC Endocrine Disorders          (2020) 20:139 Page 5 of 9
growth and adiposity, however, and our findings refute
this hypothesis, as adjuvant antenatal metformin started
in the second trimester among women who were over-
weight or obese in early pregnancy was not associated
with any differences in subcutaneous tissue fat measures
results in our cohort. Women recruited to the MiG
study had an average early pregnancy BMI of 32 kg/m2
[21], similar to women in the GRoW randomised cohort
[23]. In contrast to the MiG study, however, women re-
cruited to the GRoW randomised trial commenced
treatment much earlier in pregnancy, with an average
gestational age at trial entry of 16 weeks [23].
Our findings are in contrast to those reported in the
PregMet2 randomised trial [37], investigating the effect
of adjuvant antenatal metformin treatment among
women with polycystic ovary syndrome (PCOS), starting
in early pregnancy. While the primary outcome of this
study was late miscarriage and preterm birth, fetal and
neonatal biometry measures were performed in the third
trimester and after birth as a secondary outcome [37].

















Mid-thigh fat mass (cm2) 0.845* 0.843*
28 weeks 4.24 (1.03) 4.21 (1.09) 0.04 (−0.27, 0.35) 0.805 0.02 (− 0.29, 0.33) 0.902
36 weeks 9.87 (2.79) 9.95 (2.47) −0.05 (− 0.95, 0.84) 0.908 − 0.07 (− 0.94, 0.80) 0.870
Abdominal fat mass (mm) 0.144* 0.199*
28 weeks 3.60 (1.17) 3.60 (1.08) 0.01 (−0.31, 0.34) 0.935 0.06 (−0.27, 0.39) 0.718
36 weeks 6.42 (1.41) 5.98 (1.51) 0.42 (−0.05, 0.88) 0.077 0.42 (−0.05, 0.89) 0.079
Subscapular fat mass (mm) 0.919* 0.655*
28 weeks 3.22 (0.80) 3.20 (0.88) 0.02 (−0.21, 0.25) 0.863 0.03 (−0.19, 0.25) 0.760
36 weeks 4.84 (1.44) 4.85 (1.48) −0.00 (− 0.42, 0.41) 0.985 − 0.07 (− 0.48, 0.34) 0.740
*denotes p value for test of interaction between treatment and time, i.e. whether treatment effect varies over time

















Biparietal diameter (cm) 0.138* 0.102*
20 weeks 4.66 (0.34) 4.69 (0.35) 0.328 0.232
28 weeks 7.13 (0.50) 7.15 (0.41) −0.02 (− 0.10, 0.06) 0.645 − 0.02 (− 0.10, 0.07) 0.671
36 weeks 8.94 (0.42) 8.88 (0.39) 0.06 (−0.01, 0.14) 0.110 0.07 (− 0.01, 0.14) 0.076
Head circumference (cm) 0.299* 0.200*
20 weeks 17.38 (1.20) 17.45 (1.36) −0.07 (−0.29, 0.16) 0.551 −0.09 (− 0.31, 0.13) 0.431
28 weeks 26.46 (1.55) 26.43 (1.26) 0.04 (−0.22, 0.30) 0.744 0.05 (−0.22, 0.31) 0.727
36 weeks 32.36 (1.23) 32.20 (1.21) 0.17 (−0.05, 0.40) 0.134 0.19 (−0.04, 0.42) 0.100
Femur length (cm) 0.018* 0.012*
20 weeks 3.26 (0.30) 3.28 (0.30) −0.03 (−0.08, 0.02) 0.267 −0.04 (− 0.09, 0.01) 0.127
28 weeks 5.29 (0.37) 5.29 (0.30) 0.01 (−0.06, 0.07) 0.841 0.00 (−0.06, 0.07) 0.909
36 weeks 6.92 (0.32) 6.85 (0.33) 0.08 (0.01, 0.14) 0.015 0.07 (0.01, 0.14) 0.019
Abdominal circumference (cm) 0.992* 0.959
20 weeks 15.56 (1.37) 15.65 (1.29) −0.09 (−0.32, 0.14) 0.457 −0.10 (− 0.32, 0.12) 0.368
28 weeks 24.62 (1.75) 24.70 (1.56) −0.07 (− 0.37, 0.24) 0.669 − 0.05 (− 0.36, 0.26) 0.747
36 weeks 32.82 (1.87) 32.92 (1.99) −0.07 (− 0.43, 0.29) 0.690 − 0.07 (− 0.43, 0.29) 0.707
Estimated fetal weight (g) 0.720* 0.756*
28 weeks 1272.36 (248.33) 1268.81 (201.23) 5.05 (−36.72, 46.82) 0.813 5.40 (−36.93, 47.74) 0.803
36 weeks 2932.32 (399.97) 2914.27 (417.68) 18.98 (−56.99, 94.95) 0.624 17.61 (−57.67, 92.88) 0.647
*denotes p value for test of interaction between treatment and time, i.e. whether treatment effect varies over time
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This group found that the fetuses of women exposed to
antenatal metformin had statistically significantly larger
BPD measurements at 32 weeks’ gestation, and greater
HC measurements at birth [22]. However, the magnitude
of these differences was small – on average, less than
one centimetre – and the authors concluded that these
differences, while statistically significant, were not likely
to be clinically relevant [37]. The population of women
recruited to the PregMet2 randomised trial are different
to those women recruited to the GRoW randomised
trial, in that they all had a diagnosis of PCOS and, while
the average BMI at trial entry was 29 kg/m2, this is lower
than the average BMI at trial entry in the GRoW rando-
mised trial, which was 32 kg/m2 [23]. This study was also
smaller than the GRoW randomised trial, recruiting ap-
proximately half the number of the GRoW Trial.
Our work builds on that of two other published rando-
mised trials investigating the effect of antenatal metfor-
min among women who were obese in early pregnancy
[38, 39]. The Effect of Metformin on Maternal and Fetal
Outcomes in Obese Pregnant Women (EMPOWaR) ran-
domised trial [38] randomised women with a BMI ≥ 30
kg/m2 between 12 and 16 weeks’ gestation to receive ei-
ther metformin up to 2.5 g per day or placebo. They
found no significant difference in mean birthweight or
birthweight z-score [38], similar to the primary outcome
of the GRoW trial [23]. The second trial, Metformin in
Obese Nondiabetic Pregnant Women (MOP) trial [39],
randomised women with a BMI ≥ 35 kg/m2 between 12
and 18 weeks’ gestation, to metformin up to 3 g daily or
placebo. Similarly, they found no statistically significant
difference in birthweight z-score or incidence of neo-
natal LGA [39].
Our group has previously shown, in the LIMIT rando-
mised trial [40], that an antenatal diet and lifestyle inter-
vention in women who were overweight or obese was
associated with greater fetal mean mid-thigh fat mass,
and a significantly slower rate of subscapular adipose tis-
sue deposition, with no difference in lean thigh mass or
abdominal fat mass [33]. All women randomised to the
GRoW trial were exposed to the same dietary and life-
style intervention as was provided in the LIMIT rando-
mised trial [40]. Of interest, results of fetal biometry z
scores, estimated fetal weights and subcutaneous fat
measures obtained from fetuses of women randomised
to the GRoW trial placebo group were similar to those
found in fetuses randomised to the diet and lifestyle
group of the LIMIT randomised trial [40], providing fur-
ther support for the robustness of our measurements in
these very similar populations. While we have hypothe-
sised previously that an antenatal diet and lifestyle inter-
vention for women who were overweight or obese in
early pregnancy may be associated with a more
favourable fetal fat phenotype [33], our current findings
do not suggest that there is any further effect on fetal
adiposity with the addition of metformin to the afore-
mentioned antenatal diet and lifestyle intervention. It is
possible that the pathways involved in fetal fat depos-
ition have been “saturated” by the effect of the diet and
lifestyle intervention and cannot be further affected by
the addition of metformin.
Women recruited to the GRoW randomised trial were,
on average, 16 weeks’ gestation (Table 1). There is in-
creasing evidence that the preconceptual period is of
vital importance to healthy growth and development [41,
42]. Sovio and colleagues [43] demonstrated that the fe-
tuses of women who were obese were more likely to
have an abdominal circumference measurement greater
than the 90th percentile which was already evident at 20
weeks’ gestation. It is possible that interventions need to
be commenced prior to conception, to have an appre-
ciable effect on fetal growth and adiposity.
Conclusions
Based on our study results, there is no evidence that the
addition of metformin to dietary and lifestyle advice in
pregnancy for overweight and obese women has a clinic-
ally relevant effect on ultrasound measures of fetal biom-
etry or adiposity.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12902-020-00618-0.
Additional file 1: Supplementary Table 1. Effect of adjuvant
antenatal metformin treatment on fetal biometry z-scores across preg-
nancy. Supplementary Table 2. Effect of adjuvant antenatal metformin
treatment on fetal biometry velocities across pregnancy.
Abbreviations
GRoW randomised trial: metformin and dietary advice to improve insulin
sensitivity and promote gestational restriction of weight among pregnant
women who are overweight or obese randomised trial; MoP
study: metformin in obese non-diabetes pregnant women randomised trial;
MiG study: metformin in gestational diabetes trial; LIMIT randomised
trial: limiting weight gain in overweight and obese women during
pregnancy to improve health outcomes: a randomised trial; BMI: body mass
index; GDM: gestational diabetes; LGA: large for gestational age; HC: head
circumference; BPD: biparietal diameter; AC: abdominal circumference;
FL: femur length; EFW: estimated fetal weight; MTLM: mid-thigh lean mass;
MTFM: mid-thigh fat mass; AFM: abdominal fat mass; SSFM: subscapular fat
mass; SEIFA IRSD: socio-economic indexes for areas index of relative socio-
economic disadvantage; IQR: interquartile range
Acknowledgements
The following institutions participated in the recruitment of women to the
trial:
Women’s and Children’s Hospital (229 women); The Lyell McEwin Hospital
(238 women); Flinders Medical Centre (57 women); and the University of
Adelaide.
The following people performed research ultrasounds for the GRoW trial:
Grivell R, Poprzeczny A, O’Brien C, Raghoudi E, Waterfall H.
We are indebted to the 524 women who participated in the GRoW
randomised trial.
Poprzeczny et al. BMC Endocrine Disorders          (2020) 20:139 Page 7 of 9
Authors’ contributions
Each author fulfils the requirements for authorship. JMD and ARD were
involved in the study concept and design of the trial, supervision of conduct
of the trial and acquisition of data. AJP, JL, ARD and JMD, have been
involved equally in the development of the concept of this secondary
analysis, analysis and interpretation of data, critical review of the manuscript,
and provide approval of the final submitted version. JL was responsible for
conducting the statistical analysis. AJP drafted the manuscript, had full access
to all of the study data, and takes responsibility for the integrity of the data,
and the accuracy of the data analysis. The author(s) read and approved the
final manuscript.
Funding
The GRoW randomised trial was funded by a National Health and Medical
Research Council (NHMRC) project grant (ID 1043181). Jodie Dodd is
supported by a NHMRC Practitioner Fellowship (ID 1078980). The funding
body did not have a role in the design or running of the trial, or the final
analysis of results.
Availability of data and materials
The data that supports the findings of this study are available from the
authors upon reasonable request and cannot be made publicly available,
due to the nature of the data and the ethics approval obtained.
Ethics approval and consent to participate
The Study protocol was approved by the Women’s and Children’s Health
Network Human Research Ethics Committee (HREC/ 12/WCHN/114), with
local institutional approval at each site. Written informed consent was




The authors have no conflicts of interest to disclose. The GRoW randomised
trial was funded by a National Health and Medical Research Council (NHMR
C) project grant (ID 1043181). Jodie Dodd is supported by a NHMRC
Practitioner Fellowship (ID 1078980).
Author details
1The University of Adelaide, The Robinson Research Institute, and Discipline
of Obstetrics and Gynaecology, Adelaide, South Australia, Australia.
2Department of Perinatal Medicine, The Women’s and Children’s Hospital,
Women’s and Babies Division, Adelaide, South Australia, Australia. 3The
University of Adelaide, Women’s and Children’s Hospital, 72 King William
Road, North Adelaide, South Australia 5006, Australia. 4The University of
Adelaide, School of Public Health, Adelaide, South Australia, Australia.
Received: 3 December 2019 Accepted: 31 August 2020
References
1. Dodd JM, Grivell RM, Nguyen MA, Chan A, Robinson JS. Maternal and
perinatal health outcomes by body mass index category. Aust N Z J Obstet
Gynaecol. 2011;51(2):136–40.
2. Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Mitra A, et al.
Obesity and gynaecological and obstetric conditions: umbrella review of
the literature. BMJ. 2017;359:j4511.
3. Abenhaim HA, Kinch RA, Morin L, Benjamin A, Usher R. Effect of
prepregnancy body mass index categories on obstetrical and neonatal
outcomes. Arch Gynecol Obstet. 2007;275(1):39–43.
4. Chu SY, Kim SY, Schmid CH, Dietz PM, Callaghan WM, Lau J, et al. Maternal
obesity and risk of cesarean delivery: a meta-analysis. Obesity Rev. 2007;8(5):
385–94.
5. Australian Institute of Health and Welfare. A Picture of Overweight and
Obesity in Australia 2017. Canberra ACT; 2017. Report No.: PHE 216.
6. Dalenius K, BP, Smith B, Reinold C, Grummer-Strawn L. Pregnancy nutrition
surveillance 2010 report. Atlanta: Department of Health and Human
Services, Centers for Disease Control and Prevention; 2012.
7. Scheil WJK, Scott J, Catcheside B, Sage L, Kennare R. Pregnancy Outcome in
South Australia 2014. In: Government of South Australia, editor. Pregnancy
outcome (statistics) unit SH. Adelaide: SA Health; 2016.
8. Sebire NJ, Jolly M, Harris JP, Wadsworth J, Joffe M, Beard RW, et al. Maternal
obesity and pregnancy outcome: a study of 287,213 pregnancies in
London. Int J Obes Relat Metab Disord. 2001;25(8):1175–82.
9. Rosenberg TJ, Garbers S, Chavkin W, Chiasson MA. Prepregnancy weight
and adverse perinatal outcomes in an ethnically diverse population. Obstet
Gynecol. 2003;102(5 Pt 1):1022–7.
10. Cedergren M. Maternal morbid obesity and the risk of adverse pregnancy
outcome. Obstet Gynecol. 2004;103(2):219–24.
11. Freeman MD, Goodyear SM, Leith WM. A multistate population-based
analysis of linked maternal and neonatal discharge records to identify risk
factors for neonatal brachial plexus injury. Int J Gynaecol Obstetrics. 2017;
136(3):331–6.
12. Callaway LK, Prins JB, Chang AM, McIntyre HD. The prevalence and impact
of overweight and obesity in an Australian obstetric population. Med J Aust.
2006;184(2):56–9.
13. Doherty DA, Magann EF, Francis J, Morrison JC, Newnham JP. Pre-
pregnancy body mass index and pregnancy outcomes. Int J Gynaecol
Obstetrics. 2006;95(3):242–7.
14. Kitsantas P, Gaffney KF. Risk profiles for overweight/obesity among
preschoolers. Early Hum Dev. 2010;86(9):563–8.
15. Rooney BL, Mathiason MA, Schauberger CW. Predictors of obesity in
childhood, adolescence, and adulthood in a birth cohort. Matern Child
Health J. 2011;15(8):1166–75.
16. Jharap VV, Santos S, Steegers EA, Jaddoe VW, Gaillard R. Associations of
maternal obesity and excessive weight gain during pregnancy with
subcutaneous fat mass in infancy. Early Hum Dev. 2017;108:23–8.
17. Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA. Maternal
gestational diabetes, birth weight, and adolescent obesity. Pediatrics. 2003;
111(3):e221–6.
18. i-WIP Collaborative Group. Effect of diet and physical activity based
interventions in pregnancy on gestational weight gain and pregnancy
outcomes: meta-analysis of individual participant data from randomised
trials. BMJ. 2017;358:j3119.
19. Dodd JM, Cramp C, Sui Z, Yelland LN, Deussen AR, Grivell RM, et al. The
effects of antenatal dietary and lifestyle advice for women who are
overweight or obese on maternal diet and physical activity: the LIMIT
randomised trial. BMC Med. 2014;12(1):161.
20. Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, et al. Effect of a
behavioural intervention in obese pregnant women (the UPBEAT study): a
multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2015;
3(10):767–77.
21. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus
insulin for the treatment of gestational diabetes. N Engl J Med. 2008;
358(19):2003–15.
22. Hjorth-Hansen A, Salvesen O, Engen Hanem LG, Eggebo T, Salvesen KA,
Vanky E, et al. Fetal growth and birth anthropometrics in metformin-
exposed offspring born to mothers with PCOS. J Clin Endocrinol Metab.
2018;103(2):740–7.
23. Dodd JM, Louise J, Deussen AR, Grivell RM, Dekker G, McPhee AJ, et al.
Effect of metformin in addition to dietary and lifestyle advice for
pregnant women who are overweight or obese: the GRoW randomised,
double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;
7(1):15–24.
24. Health SA. In: Health S, editor. South Australian perinatal practice guidelines:
Normal pregnancy, labour and Puerperium management. Adelaide, South
Australia: SA Health, Government of South Australia; 2015.
25. Nisbet D, Robinson H, Halliday J, de CL. Australian Society of Ultrasound in
Medicine (ASUM) Policy Statement on normal ultrasonic fetal
measurements. Aust N Z J Obstet Gynaecol. 2002;42(1):101–3. https://doi.
org/10.1111/j.0004-8666.2002.111_5.x. PMID: 11926635.
26. Hui L. Australian charts for assessing fetal growth: a review. ASUM
Ultrasound Bulletin. 2008;2008:12–8.
27. Hadlock FP, Harrist RB, Carpenter RJ, Deter RL, Park SK. Sonographic
estimation of fetal weight. The value of femur length in addition to head
and abdomen measurements. Radiology. 1984;150(2):535–40.
28. Owen P, Harrold AJ, Farrell T. Fetal size and growth velocity in the
prediction of intrapartum caesarean section for fetal distress. Br J Obstet
Gynaecol. 1997;104(4):445–9.
Poprzeczny et al. BMC Endocrine Disorders          (2020) 20:139 Page 8 of 9
29. Gardeil F, Greene R, Stuart B, Turner MJ. Subcutaneous fat in the fetal
abdomen as a predictor of growth restriction. Obstet Gynecol. 1999;94(2):
209–12.
30. Larciprete G, Valensise H, Vasapollo B, Novelli GP, Parretti E, Altomare F,
et al. Fetal subcutaneous tissue thickness (SCTT) in healthy and gestational
diabetic pregnancies. Ultrasound Obstet Gynecol. 2003;22(6):591–7.
31. Bernstein IM, Catalano PM. Ultrasonographic estimation of fetal body
composition for children of diabetic mothers. Investig Radiol. 1991;26(8):
722–6.
32. Hill LM, Guzick D, Boyles D, Merolillo C, Ballone A, Gmiter P. Subcutaneous
tissue thickness cannot be used to distinguish abnormalities of fetal growth.
Obstet Gynecol. 1992;80(2):268–71.
33. Grivell RM, Yelland LN, Deussen A, Crowther CA, Dodd JM. Antenatal dietary
and lifestyle advice for women who are overweight or obese and the effect
on fetal growth and adiposity: the LIMIT randomised trial. BJOG. 2016;123(2):
233–43. https://doi.org/10.1111/471-0528.13777.
34. Poprzeczny AJ, Louise J, Deussen AR, Dodd JM. The mediating effects of
gestational diabetes on fetal growth and adiposity in women who are
overweight and obese: secondary analysis of the LIMIT randomised trial.
BJOG. 2018;125:1558–66.
35. Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA). In:
Statistics ABo, editor. . Australian Capital Territory: Australian Bureau of
Statistics; 2011.
36. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM.
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body
composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84.
37. Lovvik TS, Carlsen SM, Salvesen O, Steffensen B, Bixo M, Gomez-Real F, et al.
Use of metformin to treat pregnant women with polycystic ovary syndrome
(PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet
Diabetes Endocrinol. 2019;7(4):256–66.
38. Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, et al.
Effect of metformin on maternal and fetal outcomes in obese pregnant
women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol. 2015;3(10):778–86.
39. Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al.
Metformin versus placebo in obese pregnant women without diabetes
mellitus. N Engl J Med. 2016;374(5):434–43.
40. Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, et al.
Antenatal lifestyle advice for women who are overweight or obese: LIMIT
randomised trial. BMJ. 2014;348:g1285.
41. Stephenson J, Heslehurst N, Hall J, Schoenaker D, Hutchinson J, Cade JE,
et al. Before the beginning: nutrition and lifestyle in the preconception
period and its importance for future health. Lancet. 2018;391(10132):1830–
41.
42. Barker M, Dombrowski SU, Colbourn T, Fall CHD, Kriznik NM, Lawrence WT,
et al. Intervention strategies to improve nutrition and health behaviours
before conception. Lancet. 2018;391(10132):1853–64.
43. Sovio U, Murphy HR, Smith GC. Accelerated fetal growth prior to diagnosis
of gestational diabetes mellitus: a prospective cohort study of nulliparous
women. Diabetes Care. 2016;39(6):982–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Poprzeczny et al. BMC Endocrine Disorders          (2020) 20:139 Page 9 of 9
